Search results for "OUTCOME"

showing 10 items of 5148 documents

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

2017

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Result…

Blood GlucoseMalemedicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabeteslcsh:Diseases of the endocrine glands. Clinical endocrinologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agents030212 general & internal medicineDapagliflozinBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinlcsh:RC648-665business.industryType 2 Diabetes Mellitusnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomechemistryDiabetes Mellitus Type 2Observational studyDrug Therapy CombinationFemalebusinessBody mass indexmedicine.drugResearch ArticleJournal of diabetes research
researchProduct

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controll…

2009

High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentration…

Blood GlucoseMalemedicine.medical_specialtyBrachial ArteryVasodilator AgentsAdministration OralCoronary Artery DiseasePlaceboNiacinGastroenterologyCoronary artery diseaseNitroglycerinchemistry.chemical_compoundHigh-density lipoproteinDouble-Blind MethodInternal medicinemedicine.arterymedicineHumansProspective StudiesPhosphorylationEndothelial dysfunctionBrachial arteryTriglyceridesAgedUltrasonographyVascular diseasebusiness.industryCholesterol HDLMicrofilament Proteinsnutritional and metabolic diseasesCholesterol LDLMiddle AgedPhosphoproteinsmedicine.diseaseVasodilationB vitaminsTreatment OutcomeEndocrinologychemistryDelayed-Action PreparationsFemalelipids (amino acids peptides and proteins)Endothelium VascularCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersNiacinAtherosclerosis
researchProduct

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving…

2017

Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy with linagliptin 5 mg or placebo (TP 2) for one additional month. Alpha- and beta cell function were assessed with a standardised liquid meal test (LMT) and an intravenous (iv.) glucose challenge. Effi…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismLinagliptinType 2 diabetes030204 cardiovascular system & hematologyLinagliptinGlucagon03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodGlucosidesInternal medicineInsulin-Secreting CellsInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsInsulinBenzhydryl CompoundsProinsulinAgedbusiness.industryInsulinMiddle Agedmedicine.diseaseGlucagonPostprandial PeriodMetforminEndocrinologyPostprandialTreatment OutcomeDiabetes Mellitus Type 2Glucagon-Secreting CellsGlucose Clamp TechniqueFemalebusinessmedicine.drugProinsulinDiabetes, obesitymetabolism
researchProduct

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

2012

This study compared the effect of Glimepiride versus Vildagliptin on β-cell function and the release of intact proinsulin (PI) in patients with type 2 diabetes mellitus. Patients on metformin monotherapy were randomized to add on treatment with Vildagliptin or Glimepiride. A standardized test meal was given at baseline, after 12 and 24 weeks of treatment. Insulin, PI and blood glucose values were measured in the fasting state and postprandial for 300 min. Fasting PI levels significantly decreased in the Vildagliptin group. The area under the curve for the postprandial release of PI decreased during Vildagliptin and increased during Glimepiride treatment. The proinsulin to insulin ratio decl…

Blood GlucoseMalemedicine.medical_specialtyPyrrolidinesendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdamantaneEndocrinologyDiabetes mellitusInternal medicineNitrilesInternal MedicinemedicineHumansHypoglycemic AgentsVildagliptinProinsulinVildagliptinDipeptidyl-Peptidase IV Inhibitorsbusiness.industryInsulinnutritional and metabolic diseasesType 2 Diabetes MellitusPostprandial Periodmedicine.diseaseMetforminMetforminGlimepirideSulfonylurea CompoundsTreatment OutcomePostprandialEndocrinologyDiabetes Mellitus Type 2Area Under CurveDrug Therapy CombinationFemalebusinessProinsulinmedicine.drugDiabetes, Obesity and Metabolism
researchProduct

Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration

2004

Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. He…

Blood GlucoseMalemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentBlood PressureType 2 diabetesFatty Acids NonesterifiedAutonomic Nervous SystemInsulin resistanceHeart RateDiabetes mellitusInternal medicineInternal MedicineHyperinsulinemiaDiabetes MellitusMedicineHumansHypoglycemic AgentsObesityHeart rate variabilityTriglyceridesAgedGlycated HemoglobinFree fatty acidAnthropometrybusiness.industryInsulinnutritional and metabolic diseasesInsulin resistanceMiddle Agedmedicine.diseaseMetforminMetforminEndocrinologyBlood pressureTreatment OutcomeDiabetes Mellitus Type 2Multivariate AnalysisFemalebusinessHyperinsulinismBiomarkersmedicine.drug
researchProduct

A novel flash glucose monitoring system in patients with diabetes mellitus type 1 and 2: which are the pieces of evidence for payer decision-makers?

2018

A rigorous health technology assessment is necessary to evaluate a new technology. However, healthcare regulatory agencies have less restrictive rules about medical devices, despite some recent warnings about this relevant matter. The evaluation should have at least two key issues, which require attention. The first one is its effectiveness, and the second one is its economic sustainability. In this paper, we deal with a novel glucose-sensing technology as a case study to examine the matter in depth. An evidence-based point of view is used to highlight this important issue.

Blood GlucoseTechnology Assessment BiomedicalBiomedicalEconomicTechnology assessment01 natural sciencesOrganizational03 medical and health sciences0302 clinical medicineHealth careOutcome Assessment Health CareInternal MedicineMedicineHumansIn patientEthic030212 general & internal medicine0101 mathematicsBiomedical technologyMonitoring PhysiologicPoint (typography)business.industryBlood Glucose Self-Monitoring010102 general mathematicsHealth technologyMonitoring systemTechnology assessmentBiomedical technologyDiabetes Mellitus Type 1Risk analysis (engineering)Economic sustainabilityDiabetes Mellitus Type 2Emergency MedicinebusinessDecision makingInternal and emergency medicine
researchProduct

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysi…

2021

There is a large and growing body of literature focusing on the use of oral magnesium (Mg) supplementation for improving glucose metabolism in people with or at risk of diabetes. We therefore aimed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in participants with diabetes or at high risk of diabetes, compared with a placebo. Several databases were searched investigating the effect of oral Mg supplementation vs placebo in patients with diabetes or conditions at high risk of diabetes. Data were reported as standardized mean differences (SMDs) with their 95% confidence intervals (CIs) using follow-up data of glucose and insulin-sensitivity …

Blood Glucosemedicine.medical_specialtyMagnesium supplementationCarbohydrate metabolismmagnesiumPlaceboGastroenterologyArticlelaw.inventionDouble blindRandomized controlled trialDouble-Blind MethodlawDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansTX341-641glucoseRandomized Controlled Trials as TopicNutrition and Dieteticsdiabetesbusiness.industryNutrition. Foods and food supplyGlucose Tolerance Testmedicine.diseaseConfidence intervalmeta-analysisTreatment OutcomediabeteMeta-analysisDietary SupplementsInsulin ResistancebusinessFood ScienceNutrients
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.

2006

Aim. Statins are the drugs of choice in heterozygous familial hypercholesterolemia (FH), which has a high risk of premature cardiovascular events including myocardial infarction, stroke, and surgical revascularization. Methods. A 1-year open-label study was conducted to test the efficacy and tolerability of Atorvastatin titrated to the target, in proven FH patients and to evaluate certain inflammatory parameters. One hundred and two FH patients (44 men and 58 women; mean age 58.7±3.6 years) were included in the study. After evaluation using the B-mode duplex scanning system of extracranial carotid arteries, the patients were divided into groups: Group 1 (15 men, 25 women) with carotid plaqu…

Blood PlateletsCarotid Artery DiseasesMaleTime FactorsCarotid Artery CommonHyperlipoproteinemia Type IIAtorvastatinHumansPyrrolesTriglyceridesApolipoproteins BApolipoprotein A-IAnticholesteremic AgentsCholesterol HDLFibrinogenCholesterol LDLMiddle Agedhs-CRPC-Reactive ProteinTreatment OutcomeHeptanoic AcidsPatient ComplianceFemaleHeterozygous familial hypercholesterolemiaHydroxymethylglutaryl-CoA Reductase InhibitorsCarotid arteryInternational angiology : a journal of the International Union of Angiology
researchProduct